Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1

Conditions

Pericardial Effusion 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 544Pemetrexed 394pembrolizumab 373Cisplatin 358Paclitaxel 285Docetaxel 240Gemcitabine 168Nivolumab 158Erlotinib Hydrochloride 147Bevacizumab 114atezolizumab 104osimertinib 99durvalumab 92Etoposide 90Gefitinib 68130-nm albumin-bound paclitaxel 65Cetuximab 64Ipilimumab 60Drug Therapy 51Topotecan 48Injections 44tislelizumab 41Afatinib 41Cyclophosphamide 39Albumin-Bound Paclitaxel 37Vinorelbine 36Crizotinib 34cemiplimab 31icotinib 26Radiotherapy 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × NOV 002 × Thoracic × Clear all
NCT00347412 2022-07-25

Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer

Cellectar Biosciences, Inc.

Phase 3 Completed
903 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Pericardial Effusion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡